Skip to main content
. 2022 Apr 5;113(3):385–393. doi: 10.17269/s41997-022-00622-y

Table 2.

Seroprevalence according to time since vaccine receipt

Quintile Time since vaccine receipt n/N Seroprevalence
Q1 1–9 days 20/125 16.00%
Q2 10–18 days 91/123 73.98%
Q3 19–28 days 120/122 98.36%
Q4 29–46 days 126/129 97.67%
Q5 47–117 days 119/121 98.35%